Compare Globus Medical Inc. Class A Common Stock (GMED) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs ProShares UltraPro S&P500 — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while ProShares UltraPro S&P500 trades at $148.94 (market cap $5.68B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and ProShares UltraPro S&P500 for 30 Days on average.
| GMED | UPRO | |
|---|---|---|
Market Cap | $10.25B | $5.68B |
Volume | 1,059,528 | 2,478,701 |
Sector | Health | Leveraged / Inverse |
52-Week High | $96.82 | $157.66 |
52-Week Low | $58.33 | $89.29 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
UPRO trades at $155.38, showing minimal daily movement with a slight decline of 0.05%. The technical picture remains bullish with strong moving average signals, though oscillators suggest neutral momentum. Recent S&P 500 news highlights mixed sentiment with expectations of slowing profit growth alongside potential year-end rallies. The ETF's performance remains tied to broader market dynamics and index composition changes.
Outlook hinges on S&P 500 trajectory with Wall Street projecting potential gains amid valuation concerns. Key risks include market concentration in top holdings and macroeconomic pressures. The absence of fundamental ratios for UPRO requires reliance on underlying index performance and technical indicators for investment decisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
